Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00382811
Registration number
NCT00382811
Ethics application status
Date submitted
28/09/2006
Date registered
2/10/2006
Date last updated
18/07/2016
Titles & IDs
Public title
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Query!
Scientific title
Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy
Query!
Secondary ID [1]
0
0
NV06-0039
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
OVATURE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fallopian Tube Cancer
0
0
Query!
Peritoneal Neoplasms
0
0
Query!
Ovarian Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Cancer
0
0
0
0
Query!
Stomach
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - phenoxodiol
Treatment: Drugs - carboplatin
Treatment: Drugs - placebo
Experimental: 1 - Daily Phenoxodiol + weekly carboplatin
Active Comparator: 2 - Daily phenoxodiol placebo + weekly carboplatin
Treatment: Drugs: phenoxodiol
400mg phenoxodiol three times daily in 28 day cycles.
Treatment: Drugs: carboplatin
AUC=2 weekly in 28 day cycles
Treatment: Drugs: placebo
every 8 hours daily in 28 day cycles
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Progression Free Survival
Query!
Secondary outcome [1]
0
0
The secondary efficacy end-point is overall survival (OS)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Overall survival
Query!
Eligibility
Key inclusion criteria
- Histologically-confirmed ovarian, fallopian, or primary peritoneal carcinoma of
epithelial origin
- Recurrent or persistent advanced disease
- Have measurable disease
- Undergone at least two courses of therapy with a platinum drug (cisplatin or
carboplatin) and have responded to the first of those courses of therapy as determined
by either Response Evaluation Criteria in Solid Tumors (RECIST) or Gynecologic Cancer
Intergroup (GCIG) criteria
- Disease relapse as determined by either RECIST or GCIG criteria within 6 months of
completion of the second or greater course of platinum therapy using a 2-, 3- or
4-weekly regimen and platinum-free interval of no greater than 6 months at the time of
enrollment, being the time taken from the last day of platinum therapy
- Any number of previous courses of platinum therapy or non-platinum therapy
- Likely to survive at least 3 months
- Karnofsky performance score of at least 60%
- Have adequate physiological function without evidence of major organ dysfunction as
evidenced by:
- serum creatinine < 1.5 mg/dl
- serum transaminase levels = 3 x the upper limit of normal (ULN) for the reference
laboratory and
- bilirubin level < ULN
- Have adequate hematological function defined by:
- platelets > 100,000/mm3
- white cell counts (WCC) > 3,000/mm3
- neutrophils > 1,500/mm3
- hemoglobin > 8.0 g/dl
- Aged > 18
- Be able to understand the risks and benefits of the study and give written informed
consent to participation.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients with mucinous histological type of ovarian cancer
- Patients who have failed to show a clinical response (RECIST or GCIG criteria) to at
least one prior course of platinum therapy
- Patients with active infection
- Patients with concurrent severe and/or uncontrolled medical disease (e.g.,
uncontrolled diabetes, hypertension, ischemic heart disease, congestive heart failure,
etc.)
- Patients with a history of chronic active hepatitis or cirrhosis
- Patients with HIV
- Patients with active central nervous system (CNS) metastases. Patients with known CNS
metastases must have received prior radiation therapy, and CNS metastatic disease must
be stable for 4 weeks.
- Patients who have not recovered from the acute effects of any prior anti-neoplastic
therapy
- Patients with known hypersensitivity to platinum drugs that cannot be managed with
concomitant medication.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
142
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Query!
Recruitment hospital [1]
0
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [2]
0
0
Royal North Shore Hospital - Sydney
Query!
Recruitment hospital [3]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
0
0
Mater Adult Hospital - Brisbane
Query!
Recruitment hospital [5]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
- Randwick
Query!
Recruitment postcode(s) [2]
0
0
2065 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
- Westmead
Query!
Recruitment postcode(s) [4]
0
0
- Brisbane
Query!
Recruitment postcode(s) [5]
0
0
- Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Mexico
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Edegem
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
Milano
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Roma
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Bialystok
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Gdansk
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Gliwice
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Krakow
Query!
Country [27]
0
0
Poland
Query!
State/province [27]
0
0
Lublin
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Poznan
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Warszawa
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Barcelona
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Alicante
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Valencia
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Somerset
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Birmingham
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Dundee
Query!
Country [36]
0
0
United Kingdom
Query!
State/province [36]
0
0
Edinburgh
Query!
Country [37]
0
0
United Kingdom
Query!
State/province [37]
0
0
Glasgow
Query!
Country [38]
0
0
United Kingdom
Query!
State/province [38]
0
0
Leeds
Query!
Country [39]
0
0
United Kingdom
Query!
State/province [39]
0
0
London
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Nottingham
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
Sutton
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
MEI Pharma, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in
combination with weekly carboplatin, is effective against late stage ovarian cancer and to
see what, if any, side-effects of treatment may result.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00382811
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Daniel P Gold, PhD
Query!
Address
0
0
MEI Pharma, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00382811
Download to PDF